Behind the FDA Curtain: WarRoom/DailyClout Pfizer Reports cross-posted a post from FOCAL POINTS (Courageous Discourse)
Naomi Wolf and Amy Kelly May 1 · Behind the FDA Curtain: WarRoom/DailyClout Pfizer Reports This study answers one of the questions everyone has been asking about Pfizer v. Moderna. "Florida adults who received Pfizer's BNT162b2 [COVID] vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients."
NEW STUDY — Pfizer Recipients Face 37% Higher Risk of Death Than Moderna Recipients Study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause, cardiovascular, and COVID-19 mortality after Pfizer vaccination. NICOLAS HULSCHER, MPH MAY 1
READ IN APP
by Nicolas Hulscher, MPH
The study titled “Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida” was just uploaded to the MedRxiv preprint server. This study was headed by MIT Professor Retsef Levi, with Florida Surgeon General Dr. Joseph Ladapo serving as senior author:
Study Overview
Population: 1,470,100 noninstitutionalized Florida adults (735,050 Pfizer recipients and 735,050 Moderna recipients). Intervention: Two doses of either: BNT162b2 (Pfizer-BioNTech) mRNA-1273 (Moderna) Follow-up Duration: 12 months after second dose. Comparison: Head-to-head between Pfizer vs. Moderna recipients. Main Outcomes: All-cause mortality Cardiovascular mortality COVID-19 mortality Non-COVID-19 mortality All-Cause Mortality
Pfizer recipients had a significantly higher 12-month all-cause death rate than Moderna recipients — about 37% higher risk.
Pfizer Risk: 847.2 deaths per 100,000 people Moderna Risk: 617.9 deaths per 100,000 people Risk Difference: ➔ +229.2 deaths per 100,000 (Pfizer excess) Risk Ratio (RR): ➔ 1.37 (i.e., 37% higher mortality risk with Pfizer) Odds Ratio (Adjusted): ➔ 1.384 (95% CI: 1.331–1.439) Cardiovascular Mortality
Pfizer recipients had a 53% higher risk of dying from cardiovascular causes compared to Moderna recipients.
Pfizer Risk: 248.7 deaths per 100,000 people Moderna Risk: 162.4 deaths per 100,000 people Risk Difference: ➔ +86.3 deaths per 100,000 (Pfizer excess) Risk Ratio (RR): ➔ 1.53 (i.e., 53% higher cardiovascular mortality risk) Odds Ratio (Adjusted): ➔ 1.540 (95% CI: 1.431–1.657) COVID-19 Mortality
Pfizer recipients had nearly double the risk of COVID-19 death compared to Moderna recipients.
Pfizer Risk: 55.5 deaths per 100,000 people Moderna Risk: 29.5 deaths per 100,000 people Risk Difference: ➔ +26.0 deaths per 100,000 (Pfizer excess) Risk Ratio (RR): ➔ 1.88 (i.e., 88% higher COVID-19 mortality risk) Odds Ratio (Adjusted): ➔ 1.882 (95% CI: 1.596–2.220) Non-COVID-19 Mortality
Pfizer recipients faced a 35% higher risk of dying from non-COVID causes compared to Moderna recipients.
Pfizer Risk: 791.6 deaths per 100,000 people Moderna Risk: 588.4 deaths per 100,000 people Risk Difference: ➔ +203.3 deaths per 100,000 (Pfizer excess) Risk Ratio (RR): ➔ 1.35 (i.e., 35% higher non-COVID mortality risk) Odds Ratio (Adjusted): ➔ 1.356 (95% CI: 1.303–1.412) Biological Explanations
The findings of this study are surprising, given that Moderna’s mRNA-1273 vaccine contains approximately three times more mRNA (100 µg) than Pfizer’s BNT162b2 vaccine (30 µg). This suggests that the higher mortality observed among Pfizer recipients could potentially be related to higher levels of DNA contamination — an issue that has been consistently reported worldwide:
The paper hypothesizes differences between Pfizer and Moderna may be due to:
Different lipid nanoparticle compositions Differences in manufacturing, biodistribution, or storage conditions Final Conclusion
Florida adults who received Pfizer's BNT162b2 vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients.
Unfortunately, without an unvaccinated group, the study cannot determine the absolute increase in mortality risk attributable to mRNA vaccination itself. However, based on the mountain of existing evidence, it is likely that an unvaccinated cohort would have experienced much lower mortality risks. It’s also important to remember that Moderna mRNA injections are still dangerous.
As the authors conclude:
These findings are suggestive of differential non-specific effects of the BNT162b2 and mRNA-1273 COVID-19 vaccines, and potential concerning adverse effects on all-cause and cardiovascular mortality. They underscore the need to evaluate vaccines using clinical endpoints that extend beyond their targeted diseases.
Nicolas Hulscher, MPH
Epidemiologist and Foundation Administrator, McCullough Foundation
www.mcculloughfnd.org
Please consider following both the McCullough Foundation and my personal account on X (formerly Twitter) for further content. 在FDA窗帘后面：战士/ DailyClout PFizer报告过度发布了焦点（勇敢话语）Naomi Wolf和Amy Kelly 5月1·FDA窗帘后面：Warroom / DailyClout Pfizer报告这项研究 “与现代MRNA-12相比，收到辉瑞的BNT162B2 [Covid]疫苗的佛罗里达州的成年人具有更高的12个月的全因，心血管，Covid-19和非Covid-19死亡率 新的研究 - 辉瑞接受者面临比现代佛罗里达州的佛罗里达大学成人147万佛罗里达成年人的死亡风险较高37％的死亡风险较高，Joseph Ladapo总因的全部原因，心血管和Covid - Nicolas Hulscher，MPH 5月1日通过Nicolas Hulscher阅读，MPH在APP中读取了“初始Covid -19次疫苗后的12个月的全导致死亡率，在成人中的辉瑞 - Biontech或mRNA-1273疫苗接种 这项研究由MIT教授Retsef Levi领导，佛罗里达州外科医生Joseph Ladapo博士作为高级作者：学习概述人口：1,470,100毫不合理的佛罗里达成人（735,050辉瑞收件人 干预：两剂：BNT162B2（PFizer-Biontech）mRNA-1273（现代）后续持续时间：第二剂后12个月。 比较：PFizer与Moderna收件人之间的头部到头。 主要结果：全原因死亡率心血管死亡率Covid-19死亡率非Covid-19死亡率均导致死亡率富掺杂剂受到明显更高的12个月全导致死亡率，而不是现代受害者 - 风险较高约37％。 辉瑞风险：847.2人每10万人死亡现代风险：617.9每10万人死亡风险差异：➔+229.2每10万人死亡人数（辉瑞超出）风险比（RR）：➔1.37（即37％，高于37％ 辉瑞风险：248.7每10万人死亡现代风险：162.4每10万人死亡风险差异：➔+86.3每10万人死亡（辉瑞超出）风险比（RR）：➔1.53（即53％ 辉瑞风险：55.5人每10万人死亡现代风险：29.5人每10万人死亡风险差异：➔+26.0每10万人死亡人数（辉瑞超出）风险比（RR）：➔1.88（即88％，高于88％） 辉瑞风险：791.6人每10万人现代风险：588.4每10万人死亡风险差异：➔+203.3每10万人死亡人数（辉瑞超出）风险比（RR）：➔1.35（即35％ 这表明辉水剂接受者观察到的较高死亡率可能与较高水平的DNA污染有关 - 这是一遍持续报道的问题：纸张假设辉瑞和现代人之间的差异可能是由于：不同的脂质纳米粒子组合物 不幸的是，没有未接种疫苗的群体，该研究无法确定由于mRNA疫苗接种本身的死亡率风险的绝对增加。 然而，基于现有证据的山，可能会造成未接种的裁员可能会越来越低的死亡率风险。 重要的是要记住，现代MRNA注射仍然是危险的。 随着作者的结论：这些发现暗示了BNT162B2和MRNA-1273 Covid-19疫苗的微分无特异性效果，以及关于对全因和心血管死亡率的不利影响的潜力。 它们强调了使用超出其靶向疾病的临床终点来评估疫苗的需要。 Nicolas Hulscher，MPH流行病学家和基金会管理员，McCullough Foundation www.mcculloughfnd.org请考虑在X（以前推特）上的McCullough基金会和我的个人帐户进行更多内容。
NEW STUDY — Pfizer Recipients Face 37% Higher Risk of Death Than Moderna Recipients
新研究 - 辉瑞接收者面临的死亡风险比现代接受者高37％
https://open.substack.com/pub/petermcculloughmd/p/new-study-pfizer-recipients-face
Behind the FDA Curtain: WarRoom/DailyClout Pfizer Reports cross-posted a post from FOCAL POINTS (Courageous Discourse)
Naomi Wolf and Amy Kelly
May 1 · Behind the FDA Curtain: WarRoom/DailyClout Pfizer Reports
This study answers one of the questions everyone has been asking about Pfizer v. Moderna. "Florida adults who received Pfizer's BNT162b2 [COVID] vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients."
NEW STUDY — Pfizer Recipients Face 37% Higher Risk of Death Than Moderna Recipients
Study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause, cardiovascular, and COVID-19 mortality after Pfizer vaccination.
NICOLAS HULSCHER, MPH
MAY 1
READ IN APP
by Nicolas Hulscher, MPH
The study titled “Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida” was just uploaded to the MedRxiv preprint server. This study was headed by MIT Professor Retsef Levi, with Florida Surgeon General Dr. Joseph Ladapo serving as senior author:
Study Overview
Population: 1,470,100 noninstitutionalized Florida adults (735,050 Pfizer recipients and 735,050 Moderna recipients).
Intervention: Two doses of either:
BNT162b2 (Pfizer-BioNTech)
mRNA-1273 (Moderna)
Follow-up Duration: 12 months after second dose.
Comparison: Head-to-head between Pfizer vs. Moderna recipients.
Main Outcomes:
All-cause mortality
Cardiovascular mortality
COVID-19 mortality
Non-COVID-19 mortality
All-Cause Mortality
Pfizer recipients had a significantly higher 12-month all-cause death rate than Moderna recipients — about 37% higher risk.
Pfizer Risk: 847.2 deaths per 100,000 people
Moderna Risk: 617.9 deaths per 100,000 people
Risk Difference:
➔ +229.2 deaths per 100,000 (Pfizer excess)
Risk Ratio (RR):
➔ 1.37 (i.e., 37% higher mortality risk with Pfizer)
Odds Ratio (Adjusted):
➔ 1.384 (95% CI: 1.331–1.439)
Cardiovascular Mortality
Pfizer recipients had a 53% higher risk of dying from cardiovascular causes compared to Moderna recipients.
Pfizer Risk: 248.7 deaths per 100,000 people
Moderna Risk: 162.4 deaths per 100,000 people
Risk Difference:
➔ +86.3 deaths per 100,000 (Pfizer excess)
Risk Ratio (RR):
➔ 1.53 (i.e., 53% higher cardiovascular mortality risk)
Odds Ratio (Adjusted):
➔ 1.540 (95% CI: 1.431–1.657)
COVID-19 Mortality
Pfizer recipients had nearly double the risk of COVID-19 death compared to Moderna recipients.
Pfizer Risk: 55.5 deaths per 100,000 people
Moderna Risk: 29.5 deaths per 100,000 people
Risk Difference:
➔ +26.0 deaths per 100,000 (Pfizer excess)
Risk Ratio (RR):
➔ 1.88 (i.e., 88% higher COVID-19 mortality risk)
Odds Ratio (Adjusted):
➔ 1.882 (95% CI: 1.596–2.220)
Non-COVID-19 Mortality
Pfizer recipients faced a 35% higher risk of dying from non-COVID causes compared to Moderna recipients.
Pfizer Risk: 791.6 deaths per 100,000 people
Moderna Risk: 588.4 deaths per 100,000 people
Risk Difference:
➔ +203.3 deaths per 100,000 (Pfizer excess)
Risk Ratio (RR):
➔ 1.35 (i.e., 35% higher non-COVID mortality risk)
Odds Ratio (Adjusted):
➔ 1.356 (95% CI: 1.303–1.412)
Biological Explanations
The findings of this study are surprising, given that Moderna’s mRNA-1273 vaccine contains approximately three times more mRNA (100 µg) than Pfizer’s BNT162b2 vaccine (30 µg). This suggests that the higher mortality observed among Pfizer recipients could potentially be related to higher levels of DNA contamination — an issue that has been consistently reported worldwide:
The paper hypothesizes differences between Pfizer and Moderna may be due to:
Different lipid nanoparticle compositions
Differences in manufacturing, biodistribution, or storage conditions
Final Conclusion
Florida adults who received Pfizer's BNT162b2 vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients.
Unfortunately, without an unvaccinated group, the study cannot determine the absolute increase in mortality risk attributable to mRNA vaccination itself. However, based on the mountain of existing evidence, it is likely that an unvaccinated cohort would have experienced much lower mortality risks. It’s also important to remember that Moderna mRNA injections are still dangerous.
As the authors conclude:
These findings are suggestive of differential non-specific effects of the BNT162b2 and mRNA-1273 COVID-19 vaccines, and potential concerning adverse effects on all-cause and cardiovascular mortality. They underscore the need to evaluate vaccines using clinical endpoints that extend beyond their targeted diseases.
Nicolas Hulscher, MPH
Epidemiologist and Foundation Administrator, McCullough Foundation
www.mcculloughfnd.org
Please consider following both the McCullough Foundation and my personal account on X (formerly Twitter) for further content. 在FDA窗帘后面：战士/ DailyClout PFizer报告过度发布了焦点（勇敢话语）Naomi Wolf和Amy Kelly 5月1·FDA窗帘后面：Warroom / DailyClout Pfizer报告这项研究 “与现代MRNA-12相比，收到辉瑞的BNT162B2 [Covid]疫苗的佛罗里达州的成年人具有更高的12个月的全因，心血管，Covid-19和非Covid-19死亡率 新的研究 - 辉瑞接受者面临比现代佛罗里达州的佛罗里达大学成人147万佛罗里达成年人的死亡风险较高37％的死亡风险较高，Joseph Ladapo总因的全部原因，心血管和Covid - Nicolas Hulscher，MPH 5月1日通过Nicolas Hulscher阅读，MPH在APP中读取了“初始Covid -19次疫苗后的12个月的全导致死亡率，在成人中的辉瑞 - Biontech或mRNA-1273疫苗接种 这项研究由MIT教授Retsef Levi领导，佛罗里达州外科医生Joseph Ladapo博士作为高级作者：学习概述人口：1,470,100毫不合理的佛罗里达成人（735,050辉瑞收件人 干预：两剂：BNT162B2（PFizer-Biontech）mRNA-1273（现代）后续持续时间：第二剂后12个月。 比较：PFizer与Moderna收件人之间的头部到头。 主要结果：全原因死亡率心血管死亡率Covid-19死亡率非Covid-19死亡率均导致死亡率富掺杂剂受到明显更高的12个月全导致死亡率，而不是现代受害者 - 风险较高约37％。 辉瑞风险：847.2人每10万人死亡现代风险：617.9每10万人死亡风险差异：➔+229.2每10万人死亡人数（辉瑞超出）风险比（RR）：➔1.37（即37％，高于37％ 辉瑞风险：248.7每10万人死亡现代风险：162.4每10万人死亡风险差异：➔+86.3每10万人死亡（辉瑞超出）风险比（RR）：➔1.53（即53％ 辉瑞风险：55.5人每10万人死亡现代风险：29.5人每10万人死亡风险差异：➔+26.0每10万人死亡人数（辉瑞超出）风险比（RR）：➔1.88（即88％，高于88％） 辉瑞风险：791.6人每10万人现代风险：588.4每10万人死亡风险差异：➔+203.3每10万人死亡人数（辉瑞超出）风险比（RR）：➔1.35（即35％ 这表明辉水剂接受者观察到的较高死亡率可能与较高水平的DNA污染有关 - 这是一遍持续报道的问题：纸张假设辉瑞和现代人之间的差异可能是由于：不同的脂质纳米粒子组合物 不幸的是，没有未接种疫苗的群体，该研究无法确定由于mRNA疫苗接种本身的死亡率风险的绝对增加。 然而，基于现有证据的山，可能会造成未接种的裁员可能会越来越低的死亡率风险。 重要的是要记住，现代MRNA注射仍然是危险的。 随着作者的结论：这些发现暗示了BNT162B2和MRNA-1273 Covid-19疫苗的微分无特异性效果，以及关于对全因和心血管死亡率的不利影响的潜力。 它们强调了使用超出其靶向疾病的临床终点来评估疫苗的需要。 Nicolas Hulscher，MPH流行病学家和基金会管理员，McCullough Foundation www.mcculloughfnd.org请考虑在X（以前推特）上的McCullough基金会和我的个人帐户进行更多内容。